For the 1.5 million Americans living with Type 1 diabetes, each day begins with the same arithmetic: measure blood sugar, calculate insulin, inject, repeat. It's a disease of constant vigilance, where the body's own immune system has destroyed the cells that should be handling everything automatically.
Now, researchers at the Medical University of South Carolina are building something that could change that arithmetic forever — a two-part cellular therapy that doesn't just manage diabetes, but aims to cure it.
The approach, backed by $1 million from Breakthrough T1D, combines two cutting-edge technologies. First: lab-grown beta cells, the insulin-producing cells that Type 1 diabetes destroys. Second: engineered immune cells called regulatory T cells (Tregs) that act as 'bodyguards,' protecting those new beta cells from the very immune attack that caused the disease in the first place.
"We're trying to develop a therapy that would work for all people with type 1 diabetes at every stage, even people who have had the disease for many years and have no beta cells left," said Leonardo Ferreira, Ph.D., who leads the research.
The elegance is in the engineering. Ferreira's team modifies Tregs with chimeric antigen receptors (CARs) — the same technology revolutionising cancer treatment — that recognise a specific marker placed on the lab-grown beta cells. When the engineered Treg encounters a beta cell carrying that marker, it's like a lock meeting its key: the immune system stands down.
No rejection. No lifelong immunosuppressive drugs. Just a body that can, once again, make its own insulin.
The team has already shown the concept works in humanized mouse models, with protective effects lasting up to a month — the longest period tested so far. The new funding will let them explore ways to extend that protection, improve delivery, and move toward human trials.
Perhaps most remarkably, the researchers believe their approach could eventually supply beta cells not just for individual patients, but for the entire field. Lab-grown cells can be manufactured, frozen, and stored without losing quality — creating a potentially unlimited supply where donor tissue has always been scarce.
"I think this can change how medicine is done," Ferreira said. "Instead of treating symptoms, we can actually replace the missing cells."
From management to cure. That's the difference this research is chasing. 💉
